Adenocarcinoma  >>  TheraSphere (yttrium 90 microspheres)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraSphere (yttrium 90 microspheres) / Boston Scientific
NCT01434459: Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

Terminated
1
9
US
Gemcitabine with TheraSphere, TheraSphere_radioembolization, Gemcitabine- Gemzar
Emory University
Pancreatic Neoplasms, Cholangiocarcinoma
01/14
09/14
NCT00846131: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Completed
1
24
US
Sorafenib, BAY 54-9085 is the tosylate salt of BAY 43-9006; NEXAVAR®, Yttrium-90 (Y-90), Radioembolization, Therasphere
Northwestern University, National Cancer Institute (NCI)
Hepatocellular Carcinoma
07/15
09/16
NCT01864070: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Withdrawn
1
0
US
TheraSphere, Everolimus, Afinitor, Zortress, RAD001, Phone Call
M.D. Anderson Cancer Center, BTG International Inc., Novartis Pharmaceuticals
Liver Cancer
05/18
 

Download Options